| $385M | ||
| $350M | ||
| $215M | ||
| $94M | ||
| $82M | ||
| $62M |
Buys | $15,402,661 | 3 | 9 |
Sells | $11,171,069 | 31 | 91 |
| GILEAD SCIENCES, INC. | 10 percent owner | 1 | $15M | 0 | $0 | $15M |
| ROSEN TERRY J | Chief Executive Officer | 1 | $201,465 | 2 | $1.2M | $-1M |
| KANEKO YASUNORI | director | 1 | $201,200 | 0 | $0 | $201,200 |
| Markus Richard | Chief Medical Officer | 0 | $0 | 2 | $210,144 | $-210,144 |
| Azoy Alexander | Chief Accounting Officer | 0 | $0 | 6 | $300,395 | $-300,395 |
| Tang Carolyn C. | General Counsel | 0 | $0 | 2 | $318,496 | $-318,496 |
| Goeltz II Robert C. | Chief Financial Officer | 0 | $0 | 5 | $656,925 | $-656,925 |
| Jarrett Jennifer | Chief Operating Officer | 0 | $0 | 5 | $2.17M | $-2.17M |
| Jaen Juan C. | President | 0 | $0 | 9 | $6.31M | $-6.31M |
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
Over the last 12 months, insiders at Arcus Biosciences, Inc. have bought $15.4M and sold $11.17M worth of Arcus Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Arcus Biosciences, Inc. have bought $143.98M and sold $4.62M worth of stock each year.
Highest buying activity among insiders over the last 12 months: GILEAD SCIENCES, INC. (10 percent owner) — $15M. ROSEN TERRY J (Chief Executive Officer) — $201,465. KANEKO YASUNORI (director) — $201,200.
The last purchase of 19,800 shares for transaction amount of $201,465 was made by ROSEN TERRY J (Chief Executive Officer) on 2025‑02‑27.
| 2026-01-05 | Sale | Jaen Juan C. | President | 31,823 0.029% | $21.41 | $681,342 | +5.54% | |
| 2025-12-31 | Sale | Goeltz II Robert C. | Chief Financial Officer | 6,552 0.0061% | $23.38 | $153,186 | -6.40% | |
| 2025-12-18 | Sale | Azoy Alexander | Chief Accounting Officer | 4,343 0.0041% | $22.25 | $96,614 | +3.88% | |
| 2025-12-17 | Sale | ROSEN TERRY J | Chief Executive Officer | 25,744 0.0237% | $22.16 | $570,474 | +2.54% | |
| 2025-12-17 | Sale | Jaen Juan C. | President | 9,983 0.0092% | $22.16 | $221,218 | +2.54% | |
| 2025-12-17 | Sale | Jarrett Jennifer | Chief Operating Officer | 9,983 0.0092% | $22.16 | $221,218 | +2.54% | |
| 2025-12-17 | Sale | Tang Carolyn C. | General Counsel | 6,810 0.0063% | $22.16 | $150,906 | +2.54% | |
| 2025-12-17 | Sale | Goeltz II Robert C. | Chief Financial Officer | 5,960 0.0055% | $22.16 | $132,071 | +2.54% | |
| 2025-12-17 | Sale | Markus Richard | Chief Medical Officer | 4,494 0.0041% | $22.16 | $99,585 | +2.54% | |
| 2025-12-17 | Sale | Azoy Alexander | Chief Accounting Officer | 2,113 0.0019% | $22.16 | $46,823 | +2.54% | |
| 2025-12-16 | Sale | ROSEN TERRY J | Chief Executive Officer | 28,947 0.0264% | $21.88 | $633,485 | +5.13% | |
| 2025-12-16 | Sale | Jaen Juan C. | President | 11,225 0.0103% | $21.88 | $245,651 | +5.13% | |
| 2025-12-16 | Sale | Jarrett Jennifer | Chief Operating Officer | 11,225 0.0103% | $21.88 | $245,651 | +5.13% | |
| 2025-12-16 | Sale | Tang Carolyn C. | General Counsel | 7,658 0.007% | $21.88 | $167,590 | +5.13% | |
| 2025-12-16 | Sale | Goeltz II Robert C. | Chief Financial Officer | 6,702 0.0061% | $21.88 | $146,669 | +5.13% | |
| 2025-12-16 | Sale | Markus Richard | Chief Medical Officer | 5,052 0.0046% | $21.88 | $110,559 | +5.13% | |
| 2025-12-16 | Sale | Azoy Alexander | Chief Accounting Officer | 2,376 0.0022% | $21.88 | $51,997 | +5.13% | |
| 2025-12-04 | Sale | Jaen Juan C. | President | 82,997 0.0752% | $24.71 | $2.05M | -7.29% | |
| 2025-11-26 | Sale | Goeltz II Robert C. | Chief Financial Officer | 5,000 0.0045% | $25.00 | $125,000 | -6.04% | |
| 2025-11-26 | Sale | Azoy Alexander | Chief Accounting Officer | 1,900 0.0018% | $26.00 | $49,400 | -6.04% |
| GILEAD SCIENCES, INC. | 10 percent owner | 31424760 31.2153% | $685.06M | 4 | 0 | <0.0001% |
| ROSEN TERRY J | Chief Executive Officer | 2194809 2.1802% | $47.85M | 22 | 8 | <0.0001% |
| Jaen Juan C. | President | 922240 0.9161% | $20.1M | 8 | 18 | <0.0001% |
| Jarrett Jennifer | Chief Operating Officer | 193024 0.1917% | $4.21M | 0 | 29 | |
| Tang Carolyn C. | General Counsel | 124734 0.1239% | $2.72M | 0 | 8 | |
| Goeltz II Robert C. | Chief Financial Officer | 67924 0.0675% | $1.48M | 1 | 11 | +33.11% |
| Markus Richard | Chief Medical Officer | 65647 0.0652% | $1.43M | 0 | 2 | |
| KANEKO YASUNORI | director | 28400 0.0282% | $619,120.00 | 2 | 0 | <0.0001% |
| Azoy Alexander | Chief Accounting Officer | 18531 0.0184% | $403,975.80 | 0 | 10 | |
| FALBERG KATHRYN E | director | 102106 0.1014% | $2.23M | 7 | 0 | +8.71% |
| Grossman William | Chief Medical Officer | 20723 0.0206% | $451,761.40 | 3 | 5 | +93.38% |
$54,590,806 | 65 | 21.84% | $2.4B | |
$47,419,530 | 58 | 17.20% | $2.21B | |
$1,376,668 | 53 | 18.46% | $1.89B | |
$11,583,737 | 45 | 49.75% | $2.49B | |
Arcus Biosciences, Inc. (RCUS) | $571,084,134 | 44 | 4.33% | $2.19B |
$62,927,079 | 29 | 14.02% | $2.28B | |
$25,045,414 | 23 | -3.79% | $2B | |
$7,033,101 | 22 | -12.19% | $2.06B | |
$12,094,896 | 19 | 20.07% | $1.96B | |
$73,814,940 | 15 | -4.77% | $2.7B | |
$174,105,409 | 15 | 10.88% | $2.52B | |
$138,099,519 | 11 | 2.58% | $2.13B | |
$130,038,539 | 8 | 26.82% | $2.5B | |
$25,073,947 | 7 | -5.99% | $2.09B | |
$4,623,072 | 7 | 11.07% | $2.17B | |
$7,605,533 | 5 | 17.10% | $2.17B | |
$666,380 | 5 | -16.60% | $2.05B | |
$24,000,085 | 4 | 33.26% | $2.68B | |
$5,000,000 | 1 | -22.84% | $2.67B |
| Increased Positions | 96 | +45.28% | 8M | +8.27% |
| Decreased Positions | 90 | -42.45% | 7M | -7.04% |
| New Positions | 31 | New | 3M | New |
| Sold Out Positions | 28 | Sold Out | 2M | Sold Out |
| Total Postitions | 218 | +2.83% | 101M | +1.23% |
| Gilead Sciences, Inc. | $731,883.00 | 25.76% | 31.42M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $275,075.00 | 9.68% | 11.81M | +352,887 | +3.08% | 2025-09-30 |
| Vanguard Group Inc | $154,400.00 | 5.43% | 6.63M | +73,210 | +1.12% | 2025-09-30 |
| Point72 Asset Management, L.P. | $100,903.00 | 3.55% | 4.33M | -2M | -27.39% | 2025-09-30 |
| Woodline Partners Lp | $87,796.00 | 3.09% | 3.77M | -230,345 | -5.76% | 2025-09-30 |
| Suvretta Capital Management, Llc | $85,914.00 | 3.02% | 3.69M | 0 | 0% | 2025-09-30 |
| State Street Corp | $79,066.00 | 2.78% | 3.39M | -235,961 | -6.5% | 2025-09-30 |
| Siren, L.L.C. | $67,822.00 | 2.39% | 2.91M | +1M | +80.64% | 2025-09-30 |
| Fmr Llc | $53,474.00 | 1.88% | 2.3M | -277,273 | -10.78% | 2025-09-30 |
| Geode Capital Management, Llc | $37,227.00 | 1.31% | 1.6M | +2,080 | +0.13% | 2025-09-30 |